Warren Bacorro1, Alexandre Escande2, Stéphane Temam3, Isabelle Dumas4, Emilie Routier5, Marie-Catherine Gensse4, Pierre Blanchard6, François Janot3, Christine Mateus5, Yungan Tao6, Caroline Robert5, Eric Deutsch6, Christine Haie-Meder4, Cyrus Chargari7. 1. Brachytherapy Unit, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Benavides Cancer Institute, University of Santo Tomas, Manila, Philippines. 2. Brachytherapy Unit, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Oscar Lambret Cancer Center, Lille, France. 3. Department of Head-and-Neck Surgery, Gustave Roussy, Villejuif, France. 4. Brachytherapy Unit, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France. 5. Department of Dermatology, Gustave Roussy, Villejuif, France. 6. Department of Radiotherapy, Gustave Roussy, Villejuif, France. 7. Brachytherapy Unit, Gustave Roussy, Villejuif, France; Department of Radiotherapy, Gustave Roussy, Villejuif, France; Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France; French Military Health Academy, Ecole du Val-de-Grâce, Paris, France. Electronic address: cyrus.chargari@gustaveroussy.fr.
Abstract
PURPOSE: Radiotherapy of nasal carcinomas results in cure rates comparable to surgery, with anatomic preservation and good cosmesis. Brachytherapy (BT) overcomes difficulties with dosimetric coverage and affords a localized and highly conformal irradiation. We report our experience of BT for early-stage nasal squamous cell carcinomas (SCCs). METHODS AND MATERIALS: Clinical data, BT parameters, and outcome of consecutive patients treated by interstitial BT in our institute between December 1982 and April 2015 for a localized nasal SCC were examined. A total of 34 patients with newly diagnosed T1-2N0-1 nasal skin (n = 22) or nasal cavity (n = 12) SCC were identified. Implantation and dosimetry were done according to the Paris system rules. Low-dose-rate (n = 30) or pulsed-dose-rate (n = 4) techniques were used. Median dose was 70 Gy (64-75 Gy). Sites of tumor recurrence, toxicity rates, and cosmesis outcome were examined. RESULTS: Median followup time was 89 months. All patients achieved complete response. Five patients experienced local failure, with a median interval of 9 months (range, 5-12 months). Grade 3 acute reactions were reported in 2 patients (6%). Most delayed complications were mild to moderate, and good or fair cosmesis was achieved in 97%. Estimated local failure-free survival and disease-free survival rates at 5 year were 85% (95% CI = 68-94%) and 76% (95% CI = 58-88%), respectively. CONCLUSIONS: Interstitial BT is effective for selected nasal SCCs, with durable local control, acceptable toxicity, and good cosmesis.
PURPOSE: Radiotherapy of nasal carcinomas results in cure rates comparable to surgery, with anatomic preservation and good cosmesis. Brachytherapy (BT) overcomes difficulties with dosimetric coverage and affords a localized and highly conformal irradiation. We report our experience of BT for early-stage nasal squamous cell carcinomas (SCCs). METHODS AND MATERIALS: Clinical data, BT parameters, and outcome of consecutive patients treated by interstitial BT in our institute between December 1982 and April 2015 for a localized nasal SCC were examined. A total of 34 patients with newly diagnosed T1-2N0-1 nasal skin (n = 22) or nasal cavity (n = 12) SCC were identified. Implantation and dosimetry were done according to the Paris system rules. Low-dose-rate (n = 30) or pulsed-dose-rate (n = 4) techniques were used. Median dose was 70 Gy (64-75 Gy). Sites of tumor recurrence, toxicity rates, and cosmesis outcome were examined. RESULTS: Median followup time was 89 months. All patients achieved complete response. Five patients experienced local failure, with a median interval of 9 months (range, 5-12 months). Grade 3 acute reactions were reported in 2 patients (6%). Most delayed complications were mild to moderate, and good or fair cosmesis was achieved in 97%. Estimated local failure-free survival and disease-free survival rates at 5 year were 85% (95% CI = 68-94%) and 76% (95% CI = 58-88%), respectively. CONCLUSIONS: Interstitial BT is effective for selected nasal SCCs, with durable local control, acceptable toxicity, and good cosmesis.
Authors: Radouane El Ayachy; Roger Sun; Kanta Ka; Adrien Laville; Anne-Sophie Duhamel; Anne Tailleur; Isabelle Dumas; Sophie Bockel; Sophie Espenel; Pierre Blanchard; Yungan Tao; Stéphane Temam; Antoine Moya-Plana; Christine Haie-Meder; Cyrus Chargari Journal: Cancers (Basel) Date: 2021-03-19 Impact factor: 6.639